CD19 t-haNK + rituximab

CD19 t-haNK + rituximab is an investigational combination immunotherapy for relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) and Waldenstrom macroglobulinemia. The therapy consists of two components: - **CD19 t-haNK**: an allogeneic, off-the-shelf, engineered natural killer (NK) cell line that expresses a CD19-specific chimeric antigen receptor (CAR) and a high-affinity CD16 (FcγRIIIa) receptor, enabling dual anti-tumor mechanisms: direct CAR-mediated cytotoxicity against CD19+ lymphoma cells and augmented antibody-dependent cellular cytotoxicity (ADCC) when combined with monoclonal antibodies[5]. - **Rituximab**: a monoclonal antibody targeting CD20, used as standard therapy for B-cell NHL and promoting tumor cell death both directly and via ADCC. In clinical trials, patients receive a cycle of CD19 t-haNK monotherapy followed by CD19 t-haNK in combination with rituximab, targeting both CD19+ and CD20+ lymphoma cells[1][4][5]. The combination aims to increase anti-lymphoma efficacy by leveraging both CAR-NK cytotoxicity and ADCC through antibody engagement.

Other names

CD19 CAR-NK + rituximab